Pediatr. praxi. 2022;23(5):361-366 | DOI: 10.36290/ped.2022.066

Some options for preventing and treating flu-like illness

MUDr. Jan Boženský1, prof. MUDr. František Kopřiva, Ph.D.2, PharmDr. Lucie Kotlářová3, MUDr. Pavel Kostiuk, CSc.4, PharmDr. Zdeněk Procházka4
1 Dětské oddělení, Nemocnice Agel Ostrava-Vítkovice
2 Dětská klinika, Fakultní nemocnice Olomouc
3 InPharm Clinic, Jesenice u Prahy
4 Edukafarm, Jesenice u Prahy

Influenza is currently classified in a broader group known as influenza-like illness (ILI). It is a group of viral inflammations of the upper respiratory tract, which can (depending on individual reactivity) manifest a clinical picture similar to true influenza ("influenza syndrome" - mainly high temperature, cough, sore throat). In addition to the flu virus, a number of other viruses can cause these symptoms. The treatment of these diseases (except for antiviral drugs that can be used for "true" flu) is symptomatic. Stimulation of immunity plays vital role in the prevention and treatment of influenza-like ilness. The classic method of immunostimulation against influenza is vaccination. However, the effectiveness of vaccines is limited due to antigenic changes of influenza virus, moreover, it does not affect the occurrence of other viral diseases of this group. Therefore, it is advisable to use other possibilities of immunostimulating prevention of influenza-like ilness. The article deals with some possibilities of prevention and treatment of this group of diseases, based primarily on the support of the immune system.

Keywords: influenza, influenza-like illness, prevention, therapy, immunostimulation.

Published: October 11, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Boženský J, Kopřiva F, Kotlářová L, Kostiuk P, Procházka Z. Some options for preventing and treating flu-like illness. Pediatr. praxi. 2022;23(5):361-366. doi: 10.36290/ped.2022.066.
Download citation

References

  1. Babcock HM, Merz LR, Fraser VJ. Is influenza an influenza-like illness? Clinical presentation of influenza in hospitalized patients. Infect Control Hosp Epidemiol. 2006;27:266-270. Go to original source... Go to PubMed...
  2. Spencer JA, Shutt DP, Moser SK, et al. Distinguishing viruses responsible for influenza-like illness. J Theor Biol. 2022;545:111145. Go to original source... Go to PubMed...
  3. Mousa HAL. Prevention and treatment of influenza, influenza-like illness, and common cold by herbal, complementary, and natural therapies. J Evid Based Complementary Altern Med. 2017;22:166-174. Go to original source... Go to PubMed...
  4. European Food Safety Authority. Scientific Opinion on the substantiation of health claims related to vitamin C. EFSA Journal. 2010;8:1815. Go to original source...
  5. Carr AC, Maggini S. Vitamin C and immune function. Nutrients. 2017;9:1211. Go to original source... Go to PubMed...
  6. Vollbracht C, Raithel M, Krick B, et al. Intravenous vitamin C in the treatment of allergies: an interim subgroup analysis of a long-term observational study. J Int Med Res. 2018;(4)6: 3640-3655. Go to original source... Go to PubMed...
  7. Hagel AF, Layritz CM, Hagel WH, et al. Intravenous infusion of ascorbic acid decreases serum histamine concentrations in patients with allergic and non-allergic diseases. Naunyn Schmiedebergs Arch Pharmacol. 2014;386:789-793. Go to original source... Go to PubMed...
  8. Tardy AL, Pouteau E, Marquez D. Vitamins and minerals for energy, fatigue and cognition: A narrative review of biochemical and clinical evidence. Nutrients. 2020;12:228. Go to original source... Go to PubMed...
  9. Bakaev VV, Duntau AP. Ascorbic acid in blood serum of patients with pulmonary tuberculosis and pneumonia. Int J Tuberc Lung Dis. 2004;8:263-266. Go to PubMed...
  10. Hunt C, Chakravorty NK, Annan G, et al. The clinical effects of vitamin C supplementation in elderly hospitalised patients with acute respiratory infections. Int J Vitam Nutr Res. 1994;64:212-219.
  11. Uesato S, Kitagawa Y, Kaijima T, et al. Inhibitory effects of 6-O-acylated L-ascorbic acids possessing a straight- or branched-acyl chain on Epstein-Barr virus activation. Cancer Lett. 2001;166:143-146. Go to original source... Go to PubMed...
  12. Cinatl J, Cinatl J, Weber B, et al. In vitro inhibition of human cytomegalovirus replication in human foreskin fibroblasts and endothelial cells by ascorbic acid 2-phosphate. Antiviral Res. 1995;27:405-418. Go to original source... Go to PubMed...
  13. Leibovitz B, Siegel BV. Ascorbic acid and the immune response. Adv Exp Med Biol. 1981;135:1-25. Go to original source... Go to PubMed...
  14. Dey S, Bishayi B. Killing of S.aureus in murine peritoneal macrophages by ascorbic acid along with antibiotics chloramphenicol or ofloxacin: correlation with inflammation. Microb Pathog. 2018;115:239-250. Go to original source... Go to PubMed...
  15. Kim Y, Kim H, Bae S, et al. Vitamin C is an essential factor on the anti-viral immune response through the production of interferon-alpha/beta at the initial stage of influenza A virus (H3N2) infection. Immune Netw. 2013;13:70-74. Go to original source... Go to PubMed...
  16. Li W, Maeda N, Beck MA. Vitamin C deficiency increases the lung pathology of influenza virus-infected gulo-/- mice. J Nutr 2006;136:2611-2616. Go to original source... Go to PubMed...
  17. Cai Y, Li YF, Tang LP, et al. A new mechanism of vitamin C effects on A/FM/1/47(H1N1) virus-induced pneumonia in restraint-stressed mice. Biomed Res Int. 2015;2015:675149. Go to original source... Go to PubMed...
  18. Kataoka A, Imai H, Inayoshi S, et al. Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy. J Neurol Neurosurg Psy. 1993;56:1213-1216. Go to original source... Go to PubMed...
  19. Harakeh S. NF-kappa B-independent suppression of HIV expression by ascorbic acid. AIDS Res Hum Retroviruses. 1997;13:235-239. Go to original source... Go to PubMed...
  20. Hosakote YM, Jantzi PD, Esham DL, et al. Viral-mediated inhibition of antioxidant enzymes contributes to the pathogenesis of severe respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med. 2011;183:1550-1560. Go to original source... Go to PubMed...
  21. Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004;140:533-537. Go to original source... Go to PubMed...
  22. Ahn H, Park JH. Liposomal delivery systems for intestinal lymphatic drug transport. Biomater Res. 2016;20:36. Go to original source... Go to PubMed...
  23. Fan C, Pacier C, Martirosyan DM. Rose hip (Rosa canina L): A functional food perspective. Funct Foods Health Dis. 2014;4:493-509. Go to original source...
  24. Marrari LA, Terzan L, Chaufferin G. Anas barbariae for influenza treatment. Ann Ist Super Sanita. 2012;48:105-109. Go to PubMed...
  25. Casanova P, Gerard R. Bilan de 3 années d´études randomisées multicentriques Anas barbariae/placebo. Proposta Omeopatica. 1988;6:14-17.
  26. Ferley JP, Zmirou D, D´Adhemar D, et al. A controlled evaluation of a homeopathic preparation in the treatment of inluenza-like syndromes. Br J Clin Pharmacol. 1989;27:329-335. Go to original source... Go to PubMed...
  27. Papp R, Schuback G, Beck E, et al. Anas barbariae in patients with influenza-like syndromes: a placebo controlled double blind evaluation. Br Homeopath J. 1998;87:69-76. Go to original source...
  28. Colombo M, Rigamonti G, Danza ML, et al. Comparative evaluation of Guna-Flu vs vaccine for the prevention of influenza syndrome in paediatrics - a prospective, multicentric randomized, controlled clinical trial. Physiological Regulating Medicine. 2007;2(1):3-10.
  29. Supino C. Prevenzione delle infezioni delle alte vie respiratporie in eta pediatrica con Omeogriphi: studio multicentrico controllato. La Medicina Biologica. 2002;20(3): 19-23.
  30. Arrighi A. Omeogriphi vs. paracetamolo nel trattamento della sindrome influenzale - studio clinico prosperrico controllato. La Medicina Biologica. 2013;31(4):3-12.




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.